Kyverna Therapeutics KYTX
NASDAQ KYTX
$5.12 +0.04 (+0.79%)
At close: Nov 11, 2026 · 4:00 PM EST

Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2022 - 2023)

Updated

Kyverna Therapeutics (KYTX) recorded Preferred Stock Liabilities of $180.57 million in Q4 2023, unchanged from the prior quarter.

Analysis

Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Starting with Q1 2023, Kyverna Therapeutics' Preferred Stock Liabilities history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at $180.57 million (Q3 2023), $145.73 million (Q2 2023) and $120.67 million (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Kyverna Therapeutics 312.78 Mn -573.60 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 180.57 Mn
Sep 30, 2023 180.57 Mn
Jun 30, 2023 145.73 Mn
Mar 31, 2023 120.67 Mn
Dec 31, 2022 120.67 Mn
API Access

Kyverna Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=KYTX&period=max&api_key=YOUR_API_KEY